Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$193 Mln
P/E Ratio
--
P/B Ratio
0.64
Industry P/E
--
Debt to Equity
0.15
ROE
-0.24 %
ROCE
-21.66 %
Div. Yield
0 %
Book Value
5.2
EPS
-1.13
CFO
$-126.50 Mln
EBITDA
$-238.13 Mln
Net Profit
$-229.37 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Voyager Therapeutics (VYGR)
| -38.98 | -11.51 | -38.43 | -54.29 | -22.66 | -20.91 | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Voyager Therapeutics (VYGR)
| -32.60 | 38.36 | 125.09 | -62.10 | -48.75 | 48.40 | -43.20 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.10 | 10,135.98 | 20.78 | 23.13 | |
| 298.01 | 8,668.61 | 21.55 | 58.42 | |
| 27.39 | 9,559.25 | -- | -28.77 | |
| 106.95 | 10,030.35 | 30.81 | 14.16 |
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its... product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial. The company is also developing VY-FXN01 for treating friedreich's ataxia; and GBA1 gene replacement program to treat parkinson's disease. In addition, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Neurocrine Biosciences, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. Address: 75 Hayden Avenue, Lexington, MA, United States, 02421 Read more
President, CEO & Director
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
President, CEO & Director
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
Headquarters
Lexington, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Voyager Therapeutics Inc (VYGR) stood at $ 393 Mln as on 31-Dec-24
The share price of Voyager Therapeutics Inc (VYGR) is $3.46 (NASDAQ) as of 25-Apr-2025 13:39 EDT. Voyager Therapeutics Inc (VYGR) has given a return of -22.66% in the last 3 years.
Voyager Therapeutics Inc (VYGR) has a market capitalisation of $ 193 Mln as on 24-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Voyager Therapeutics Inc (VYGR) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Voyager Therapeutics Inc (VYGR) and enter the required number of quantities and click on buy to purchase the shares of Voyager Therapeutics Inc (VYGR).
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial. The company is also developing VY-FXN01 for treating friedreich's ataxia; and GBA1 gene replacement program to treat parkinson's disease. In addition, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Neurocrine Biosciences, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. Address: 75 Hayden Avenue, Lexington, MA, United States, 02421
The CEO & director of Dr. Alfred W. Sandrock Jr., M.D., Ph.D.. is Voyager Therapeutics Inc (VYGR), and CFO & Sr. VP is Dr. Alfred W. Sandrock Jr., M.D., Ph.D..
There is no promoter pledging in Voyager Therapeutics Inc (VYGR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Voyager Therapeutics Inc. (VYGR) | Ratios |
|---|---|
|
Return on equity(%)
|
-24.25
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-81.25
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Voyager Therapeutics Inc (VYGR) was $0 Mln.
$-0.07
(
